IL277095B1 - Preparations containing anti-PD-1 antibody - Google Patents

Preparations containing anti-PD-1 antibody

Info

Publication number
IL277095B1
IL277095B1 IL277095A IL27709520A IL277095B1 IL 277095 B1 IL277095 B1 IL 277095B1 IL 277095 A IL277095 A IL 277095A IL 27709520 A IL27709520 A IL 27709520A IL 277095 B1 IL277095 B1 IL 277095B1
Authority
IL
Israel
Prior art keywords
pharmaceutical composition
seq
amino acid
acid sequence
sequence shown
Prior art date
Application number
IL277095A
Other languages
Hebrew (he)
Other versions
IL277095A (en
IL277095B2 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL277095A publication Critical patent/IL277095A/en
Publication of IL277095B1 publication Critical patent/IL277095B1/en
Publication of IL277095B2 publication Critical patent/IL277095B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Claims (18)

277095/ - 66 - CLAIMS
1. A pharmaceutical composition comprising or consisting of: an anti-PD-1 antibody of 150 mg/ml; a histidine buffer of 20 mM ; a disaccharide of 84 mg/ml trehalose; 0.2 mg/ml PS80; and a chelating agent of 0.045 or 0.05 mg/ml EDTA, wherein said pharmaceutical composition is pH 5.0 +/- 0.1, and the anti-PD-1 antibody is an IgG4 human or humanized monoclonal antibody comprising a heavy chain variable region (VH) comprising a VH complementarity determining region one (CDR1), a VH CDR2, and a VH CDR3; and a light chain variable region (VL) comprising a VL CDR1, a VL CDR2, and a VL CDR3, wherein the VH CDR1 comprises the amino acid sequence shown in SEQ ID NO: 4, the VH CDR2 comprises the amino acid sequence shown in SEQ ID NO: 5, and the VH CDR3 comprises the amino acid sequence shown in SEQ ID NO: 6, the VL CDR1 comprises the amino acid sequence shown in SEQ ID NO: 7, the VL CDR2 comprises the amino acid sequence shown in SEQ ID NO: 8, and the VL CDR3 comprises the amino acid sequence shown in SEQ ID NO: 9.
2. The pharmaceutical composition of claim 1, wherein the viscosity of the composition is between 10 cP and 18 cP at at 20ºC.
3. The pharmaceutical composition of claim 2, wherein the viscosity of the composition is 15 cP at 20ºC.
4. The pharmaceutical composition of claim 1, comprising or consisting essentially of: 150 mg/ml anti-PD-1 antibody; mM histidine buffer; 100 mM arginine HCl; mg/ml trehalose; 277095/ - 67 - 0.2 mg/ml PS80; and 0.045 or 0.05 mg/ml EDTA, wherein said pharmaceutical composition is pH 5.0 +/- 0.1.
5. The pharmaceutical composition of claim 4, wherein the viscosity of the composition is between 10 cP and 18 cP at at 20ºC.
6. The pharmaceutical composition of claim 5, wherein the viscosity of the composition is 15 cP at 20ºC.
7. The pharmaceutical composition of any one of claims 1 to 6 , wherein the EDTA comprises disodium EDTA, disodium EDTA dihydrate, or a combination of disodium EDTA and disodium EDTA dihydrate.
8. The pharmaceutical composition of any one of claims 1 to 7 , wherein the antibody is an human or humanized IgG4 monoclonal antibody comprising a heavy chain variable region (VH) comprising the amino acid sequence shown in SEQ ID NO: 2, and a light chain variable region (VL) comprising the amino acid sequence shown in SEQ ID NO: 3.
9. The pharmaceutical composition of any one of claims 1 to 8, wherein the antibody comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 10, with or without the C-terminal lysine of SEQ ID NO: 10; and a light chain comprising the amino acid sequence shown in SEQ ID NO: 11.
10. The pharmaceutical composition of claim 9, wherein the antibody displays glycosylation at Asn294 comprising G0F and G1F as the main glycan species.
11. The pharmaceutical composition of claim 10, wherein the glycosylation further comprises as minor glycan species truncated and/or afucosylated complex-type biantennary structures, a high mannose-type Man5 structure, and sialylated, core-fucosylated complex-type biantennary oligosaccharides.
12. A pharmaceutical composition comprising or consisting essentially of: 150 mg/ml anti-PD-1 antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO: 10, with or 277095/ - 68 - without the C-terminal lysine of SEQ ID NO: 10; and a light chain comprising the amino acid sequence shown in SEQ ID NO: 11; mM histidine buffer; mg/ml trehalose; 0.2 mg/ml PS80; and 0.045 or 0.05 mg/ml EDTA, wherein said pharmaceutical composition is pH 5.0 +/- 0.1 and has a viscosity of to 18 cP at 20ºC.
13. The pharmaceutical composition of claim 12, wherein the EDTA comprises disodium EDTA, disodium EDTA dihydrate, or a combination of disodium EDTA and disodium EDTA dihydrate.
14. The pharmaceutical composition of claim 12 or 13, wherein the trehalose is trehalose dihydrate.
15. The pharmaceutical composition of any one of claims 1 to 14, wherein the pharmaceutical composition does not comprise an anti-oxidant.
16. The pharmaceutical composition of claim 15, wherein the anti-oxidant is L-methionine, or a pharmaceutically acceptable salt thereof.
17. The pharmaceutical composition of any one of claims 1 to 16, wherein the pharmaceutical composition does not comprise methionine.
18. The pharmaceutical composition of any one of claims 1 to 17, wherein the pharmaceutical composition does not comprise arginine.
IL277095A 2018-03-07 2019-03-03 Anti-pd-1 antibody compositions IL277095B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862639587P 2018-03-07 2018-03-07
US201962807912P 2019-02-20 2019-02-20
PCT/IB2019/051733 WO2019171253A1 (en) 2018-03-07 2019-03-04 Anti-pd-1 antibody compositions

Publications (3)

Publication Number Publication Date
IL277095A IL277095A (en) 2020-10-29
IL277095B1 true IL277095B1 (en) 2025-06-01
IL277095B2 IL277095B2 (en) 2025-10-01

Family

ID=66041593

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277095A IL277095B2 (en) 2018-03-07 2019-03-03 Anti-pd-1 antibody compositions

Country Status (10)

Country Link
US (1) US20210002369A1 (en)
EP (1) EP3761954A1 (en)
JP (1) JP7312188B2 (en)
KR (1) KR102594028B1 (en)
CN (1) CN112105343B (en)
AU (1) AU2019232625B2 (en)
BR (1) BR112020017935A2 (en)
IL (1) IL277095B2 (en)
MX (1) MX2020009275A (en)
WO (1) WO2019171253A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
PE20212185A1 (en) 2019-02-18 2021-11-11 Lilly Co Eli FORMULATION OF THERAPEUTIC ANTIBODIES
AU2020385048A1 (en) * 2019-11-13 2022-06-02 Pfizer Inc. Stable aqueous anti-TFPI antibody formulation
TW202138006A (en) * 2019-12-13 2021-10-16 韓商三星Bioepis股份有限公司 Stable anti-pd-1 antibody pharmaceutical formulations
US20230355757A1 (en) 2019-12-20 2023-11-09 Formycon Ag Formulations of anti-pd1 antibodies
WO2021152175A1 (en) * 2020-01-31 2021-08-05 Sanofi Pulmonary delivery of antibodies
CA3181776A1 (en) 2020-05-26 2021-12-02 Boehringer Ingelheim International Gmbh Anti-pd-1 antibodies
CN113967195A (en) * 2020-07-22 2022-01-25 三生国健药业(上海)股份有限公司 anti-HER 2/PD1 bispecific antibody lyophilized preparation and preparation method thereof
CN114652824A (en) * 2020-12-23 2022-06-24 上海药明生物技术有限公司 anti-EGFR and PD-1 bispecific antibody formulations and methods of preservation
US20240287185A1 (en) 2021-06-23 2024-08-29 Formycon Ag Formulations of anti-pd1 antibodies
CN117881419A (en) * 2021-07-01 2024-04-12 天津立博美华基因科技有限责任公司 Drug combinations and their uses
CA3224640A1 (en) * 2021-07-09 2023-01-12 Krishnan SAMPATHKUMAR Pharmaceutical compositions of a pd-1 antibody and use of the same
JP2024532462A (en) * 2021-09-03 2024-09-05 ドクター レディズ ラボラトリーズ リミテッド Methods for improving the stability of immune checkpoint inhibitors
CN118076380A (en) * 2021-09-03 2024-05-24 雷迪博士实验室有限公司 Pharmaceutical formulations of immune checkpoint inhibitors
MX2024009994A (en) * 2022-03-07 2024-08-22 Mabxience Res S L Stable formulations for antibodies.
US20260207493A1 (en) * 2022-12-21 2026-07-23 Formycon Ag Formulations of anti-pd1 antibodies
WO2024171082A1 (en) 2023-02-16 2024-08-22 Sun Pharmaceutical Industries Limited Stable protein compositions of anti-pd1 antibody
TW202508641A (en) * 2023-08-16 2025-03-01 大陸商上海邁晉生物醫藥科技有限公司 A pharmaceutical composition containing immune conjugate and use thereof
WO2025174319A1 (en) * 2024-02-16 2025-08-21 Xbrane Biopharma Ab Stable antibody formulation for intravenous use comprising nivolumab, histidine, sucrose, polysorbate and methionine
SE548163C2 (en) * 2024-02-16 2026-04-13 Xbrane Biopharma Ab Stable antibody formulation comprising nivolumab, histidine, sucrose, polysorbate and methionine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048520A1 (en) * 2013-09-27 2015-04-02 Genentech, Inc. Anti-pdl1 antibody formulations
US20160159905A1 (en) * 2014-12-09 2016-06-09 Rinat Neuroscience Corp. Anti-pd-1 antibodies and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
CA2602316A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (en) 2007-06-18 2014-01-07 Merck Sharp & Dohme ANTIBODIES FOR THE PD-1 PROGRAMMED DEATH HUMAN RECEPTOR
EA201500417A1 (en) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. ANTAGONIST COMPOSITIONS PD-1 AND APPLICATIONS
MX2012012927A (en) * 2010-05-06 2013-05-01 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies.
BR112013025845A2 (en) * 2011-04-07 2018-09-04 Glaxosmithkline Llc low viscosity formulations
TWI731535B (en) * 2014-03-21 2021-06-21 美商艾伯維有限公司 Anti-egfr antibodies and antibody drug conjugates
TW201617368A (en) * 2014-09-05 2016-05-16 史坦森特瑞斯公司 Novel anti-MFI2 antibody and method of use
WO2016120753A1 (en) * 2015-01-28 2016-08-04 Pfizer Inc. Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation
EP3357508A4 (en) * 2015-09-28 2019-04-24 Suzhou Suncadia Biopharmaceuticals Co., Ltd. PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODIES AND APPLICATION THEREOF IN A MEDICAMENT
WO2017055966A1 (en) * 2015-10-01 2017-04-06 Pfizer Inc. Low viscosity antibody compositions
SG11201909941QA (en) * 2017-05-02 2019-11-28 Merck Sharp & Dohme Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048520A1 (en) * 2013-09-27 2015-04-02 Genentech, Inc. Anti-pdl1 antibody formulations
US20160159905A1 (en) * 2014-12-09 2016-06-09 Rinat Neuroscience Corp. Anti-pd-1 antibodies and methods of use thereof

Also Published As

Publication number Publication date
JP2021517129A (en) 2021-07-15
BR112020017935A2 (en) 2021-02-09
AU2019232625A1 (en) 2020-09-17
CA3093036A1 (en) 2019-09-12
AU2019232625B2 (en) 2025-12-11
EP3761954A1 (en) 2021-01-13
CN112105343B (en) 2024-07-30
RU2020129226A3 (en) 2022-04-07
KR20200128115A (en) 2020-11-11
US20210002369A1 (en) 2021-01-07
CN112105343A (en) 2020-12-18
KR102594028B1 (en) 2023-10-24
JP7312188B2 (en) 2023-07-20
WO2019171253A8 (en) 2020-10-01
IL277095A (en) 2020-10-29
WO2019171253A1 (en) 2019-09-12
IL277095B2 (en) 2025-10-01
RU2020129226A (en) 2022-04-07
MX2020009275A (en) 2021-01-08

Similar Documents

Publication Publication Date Title
IL277095B2 (en) Anti-pd-1 antibody compositions
JP7375122B2 (en) Humanized, murine or chimeric anti-CD47 monoclonal antibodies
JP2021517129A5 (en)
JP4879884B2 (en) Anti-IL-9 antibody preparation and use thereof
US12264199B2 (en) Anti-HLA-G antibodies, compositions comprising anti-HLA-G antibodies and methods of using anti-HLA-G antibodies
ES2433092T3 (en) Compositions and production procedures of a composition
ES2626033T3 (en) High concentration antibody formulations
JP5933975B2 (en) Antibody preparation
NZ719036A (en) Anti-pdl1 antibody formulations
RU2012131099A (en) ANTIBODY DRUG
JP2020015719A (en) Pertuzumab variants and evaluation thereof
PE20240814A1 (en) STABLE FORMULATIONS OF ANTIBODIES AGAINST THE PROGRAMMED DEATH 1 (PD-1) RECEPTOR AND METHODS FOR THEIR USE
US20220056126A1 (en) Anti-lag-3 antibodies and compositions
JP2020518600A5 (en)
CO6251275A2 (en) FORMULATIONS OF LIOFILIZED IMMUNOGLOBULIN AND METHODS FOR PREPARATION
CN111971062A (en) Monoclonal antibody preparation for resisting human PD-1, combined medicament and application thereof
HRP20211444T1 (en) Anti-dll3 antibody
JP2020518598A5 (en)
MY182680A (en) Antibody formulation and therapeutic regimens
PE20140882A1 (en) NEUTRALIZING ANTIBODIES OF HUMAN CYTOMEGALOVIRUS
CA3091174A1 (en) B7-h4 antibody formulations
JP2020518600A (en) Stable formulations of anti-TIGIT antibodies, alone and in combination with programmed death receptor 1 (PD-1) antibodies, and methods of use thereof
JP2016533335A5 (en)
HRP20230146T1 (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
WO2017060322A3 (en) Ptefb-inhibitor-adc